CA2060154A1 - Angiotensin ii receptor blocking quinazolones - Google Patents

Angiotensin ii receptor blocking quinazolones

Info

Publication number
CA2060154A1
CA2060154A1 CA002060154A CA2060154A CA2060154A1 CA 2060154 A1 CA2060154 A1 CA 2060154A1 CA 002060154 A CA002060154 A CA 002060154A CA 2060154 A CA2060154 A CA 2060154A CA 2060154 A1 CA2060154 A1 CA 2060154A1
Authority
CA
Canada
Prior art keywords
carbon atoms
lower alkyl
quinazolinone
butyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002060154A
Other languages
English (en)
French (fr)
Inventor
Aranapakam M. Venkatesan
Jeremy I. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2060154A1 publication Critical patent/CA2060154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Fats And Perfumes (AREA)
CA002060154A 1991-01-30 1992-01-28 Angiotensin ii receptor blocking quinazolones Abandoned CA2060154A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64849291A 1991-01-30 1991-01-30
US07/648,492 1991-01-30

Publications (1)

Publication Number Publication Date
CA2060154A1 true CA2060154A1 (en) 1992-07-31

Family

ID=24601009

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002060154A Abandoned CA2060154A1 (en) 1991-01-30 1992-01-28 Angiotensin ii receptor blocking quinazolones

Country Status (23)

Country Link
US (2) US5290780A (enExample)
EP (1) EP0497150B1 (enExample)
JP (1) JP2758766B2 (enExample)
KR (1) KR920014805A (enExample)
CN (1) CN1037440C (enExample)
AT (1) ATE164158T1 (enExample)
AU (2) AU642573B2 (enExample)
CA (1) CA2060154A1 (enExample)
CZ (1) CZ281429B6 (enExample)
DE (1) DE69224763T2 (enExample)
DK (1) DK0497150T3 (enExample)
ES (1) ES2117014T3 (enExample)
FI (1) FI920217A7 (enExample)
GR (1) GR3026592T3 (enExample)
HU (1) HUT61748A (enExample)
IE (1) IE920142A1 (enExample)
IL (1) IL100711A0 (enExample)
NO (1) NO920298L (enExample)
NZ (1) NZ241343A (enExample)
PL (1) PL293316A1 (enExample)
SK (1) SK279004B6 (enExample)
TW (1) TW282467B (enExample)
ZA (1) ZA92392B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
DK0618207T3 (da) * 1993-03-24 1999-08-30 American Home Prod Substituerede pyridopyrimidiner som antihypertensiva
US5358951A (en) * 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
US5610301A (en) * 1993-07-01 1997-03-11 American Cyanamid Company Process for the regioselective n-alkylation of quinazolinones
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US5338736A (en) * 1993-10-07 1994-08-16 American Cyanamid Company Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
ATE176784T1 (de) * 1994-09-20 1999-03-15 Wakunaga Seiyaku Kk Verfahren zur herstellung von n- biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
US5760220A (en) * 1995-06-07 1998-06-02 American Home Products Corporation Process for preparation of biphenyl derivatives
EP0846117B1 (en) * 1995-06-07 2003-05-14 Wyeth Process for preparation of biphenyl derivatives
US5739330A (en) * 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
US5763608A (en) * 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
US20060047952A1 (en) * 2002-10-18 2006-03-02 Koninklijke Philips Electronics, N.V. Method, system, device , signal and computer program product for metadata protection in tv-anytime
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
CN107056715B (zh) * 2017-04-07 2019-07-30 江南大学 一种增强TRPV4-KCa2.3复合体耦联度的化合物及其在抗高血压中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
CS272018B1 (en) * 1988-11-01 1990-12-13 Fisnerova Ludmila Ethereal derivatives of 4/3h/-quinazolinone
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5240928A (en) * 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones

Also Published As

Publication number Publication date
CS25592A3 (en) 1992-08-12
JPH0578332A (ja) 1993-03-30
FI920217L (fi) 1992-07-31
US5405849A (en) 1995-04-11
DK0497150T3 (da) 1998-06-02
EP0497150A1 (en) 1992-08-05
ZA92392B (en) 1992-10-28
AU1039792A (en) 1992-08-06
HU9200278D0 (en) 1992-04-28
JP2758766B2 (ja) 1998-05-28
KR920014805A (ko) 1992-08-25
EP0497150B1 (en) 1998-03-18
AU642573B2 (en) 1993-10-21
CZ281429B6 (cs) 1996-09-11
NO920298D0 (no) 1992-01-22
AU647992B2 (en) 1994-03-31
SK279004B6 (sk) 1998-05-06
IL100711A0 (en) 1992-09-06
CN1066847A (zh) 1992-12-09
ATE164158T1 (de) 1998-04-15
CN1037440C (zh) 1998-02-18
ES2117014T3 (es) 1998-08-01
IE920142A1 (en) 1992-07-29
FI920217A0 (fi) 1992-01-17
TW282467B (enExample) 1996-08-01
NZ241343A (en) 1994-06-27
NO920298L (no) 1992-07-31
DE69224763T2 (de) 1998-07-09
HUT61748A (en) 1993-03-01
FI920217A7 (fi) 1992-07-31
PL293316A1 (en) 1993-08-23
AU4490693A (en) 1993-11-18
US5290780A (en) 1994-03-01
GR3026592T3 (en) 1998-07-31
DE69224763D1 (de) 1998-04-23

Similar Documents

Publication Publication Date Title
EP0497150B1 (en) Angiotensin II receptor blocking 2,3,6-substituted quinazolones
JP3117721B2 (ja) 新規なベンジルピリミジン類
US5389641A (en) Fused heterocyclic compounds, having angiotensin II antagonistic activity
CA2080705C (en) Substituted pyrimidines
US7022860B2 (en) Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
JPH05239053A (ja) キノリン誘導体ならびにその製造方法および治療への応用
JPH0725870A (ja) アンジオテンシンｉｉ受容体ブロツキング性の２，３，６−置換されたキナゾリノン類
US5281603A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5294617A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
HU196989B (en) Process for producing quinoline derivatives and pharmaceuticals comprising same
US5281604A (en) Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
CA2086647A1 (en) Chemical process
US7091222B2 (en) Imidazole derivatives
US5284853A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5292734A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
KR0132001B1 (ko) 신규한 치환된 이미다졸 유도체
US5284852A (en) Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
US5294611A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
WO2000050416A1 (en) 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
US5292742A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
JP3466694B2 (ja) ピラゾロ〔１，５−ａ〕ピリミジン−７（４Ｈ）−オン誘導体
US5286729A (en) Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
AU669966B2 (en) Substituted pyridopyrimidines as antihypertensives
US5338736A (en) Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
JP2548511B2 (ja) ３−（６−キノリルメチル）−４ｈ−イミダゾール−４−オン誘導体、その製造と医療への応用

Legal Events

Date Code Title Description
FZDE Discontinued